Risedronic Acid

Summary

Risedronic Acid (CHEMBL923) is an approved small molecule (ATC M05BA07) targeting FDPS; indicated across 13 conditions including bone disorder and osteoporosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M05BA07
• Targets: 1 (FDPS)
• Indications: 13 conditions
• Clinical trials: 77
• Chemistry: 283.11 Da · C7H11NO7P2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL923
Name	Risedronic Acid
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5245
ATC	M05BA07
Molecular formula	C7H11NO7P2
Molecular weight	283.11
InChIKey	IIDJRNMFWXDHID-UHFFFAOYSA-N

SMILES: C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O

IUPAC name: (1-hydroxy-1-phosphono-2-pyridin-3-ylethyl)phosphonic acid

Also known as: Acide risedronique, Acido risedronico, M05BA07, Ridron, Risedronate, Risedronic acid, risedronate, SID29216086, risedronic acid, RISEDRONIC ACID, Risedronate sodiumÊ, Risedronate sodiumÂ

Parent form; salt/anhydrous children: CHEMBL1654, CHEMBL3560765, CHEMBL4303174

Patent coverage: 5,624 distinct patent families (22,719 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 22,705 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
FDPS	farnesyl diphosphate synthase	Inhibition	6.34	72.4%	P14324

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Farnesyl pyrophosphate synthase, cGMP-inhibited 3’,5’-cyclic phosphodiesterase 3A, Butyrophilin subfamily 3 member A1.

Bioactivity

ChEMBL activities: 26 potent at pChembl ≥ 5 of 26 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FDPS	9.44	IC50	0.36	nM	CHEMBL_ACT_15249474
FDPS	9.44	Ki	0.36	nM	CHEMBL_ACT_2155085
FDPS	8.41	IC50	3.9	nM	CHEMBL_ACT_24973371
FDPS	8.28	IC50	5.2	nM	CHEMBL_ACT_13828730
FDPS	8.24	IC50	5.7	nM	CHEMBL_ACT_2155084
FDPS	8.24	IC50	5.7	nM	CHEMBL_ACT_2168187
FDPS	8.22	IC50	6	nM	CHEMBL_ACT_15049511
FDPS	8.22	IC50	6	nM	CHEMBL_ACT_15240662
FDPS	8	IC50	10	nM	CHEMBL_ACT_12049466
FDPS	8	IC50	10	nM	CHEMBL_ACT_18897262
FDPS	8	IC50	10	nM	CHEMBL_ACT_903948
FDPS	7.96	IC50	11	nM	CHEMBL_ACT_10945289
FDPS	7.96	IC50	11	nM	CHEMBL_ACT_11013271
FDPS	7.96	IC50	11	nM	CHEMBL_ACT_13828742
FDPS	7.96	IC50	11	nM	CHEMBL_ACT_15191325
FDPS	7.8	Ki	16	nM	CHEMBL_ACT_1084769
FDPS	7.16	IC50	70	nM	CHEMBL_ACT_18768144
BTN3A1	7.1	EC50	80	nM	CHEMBL_ACT_22408119
FDPS	7.09	IC50	82	nM	CHEMBL_ACT_15249476
FDPS	7.08	Ki	82.2	nM	CHEMBL_ACT_2155041
FDPS	6.77	IC50	170	nM	CHEMBL_ACT_1084768
FDPS	6.77	IC50	169.8	nM	CHEMBL_ACT_1084770
FDPS	6.52	IC50	300	nM	CHEMBL_ACT_3500352
FDPS	6.34	IC50	452.9	nM	CHEMBL_ACT_2155040
FDPS	6.07	IC50	860	nM	CHEMBL_ACT_10946195
PDE3A	5.15	AC50	7141	nM	CHEMBL_ACT_25190226

Target pathways

Aggregated over 1 target gene(s): FDPS.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Cholesterol biosynthesis	1	FDPS
Activation of gene expression by SREBF (SREBP)	1	FDPS
Lanosterol biosynthesis	1	FDPS

Dominant GO biological processes

GO term	Targets
cholesterol biosynthetic process	1
geranyl diphosphate biosynthetic process	1
trans, trans-farnesyl diphosphate biosynthetic process	1
lipid metabolic process	1
steroid biosynthetic process	1
steroid metabolic process	1
cholesterol metabolic process	1
isoprenoid biosynthetic process	1
sterol biosynthetic process	1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bone disorder	4	MONDO:0005381	EFO:0004260

8 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
osteoporosis	3	MONDO:0005298	EFO:0003882
postmenopausal osteoporosis	3	MONDO:0008159	EFO:0003854
metastatic prostate carcinoma	3	MONDO:0004956	EFO:0000196
bone Paget disease	3	MONDO:0005382	EFO:0004261
spinal cord injury	3	MONDO:0043797	EFO:1001919
lung neoplasm	2	MONDO:0021117	MONDO:0021117
fibrous dysplasia	2	MONDO:0000845	MONDO:0000845
renal osteodystrophy	1	MONDO:0006946	EFO:1001152

4 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 77.

Phase distribution

Phase	Trials
PHASE3	31
PHASE4	27
PHASE2	7
Not specified	6
PHASE1	4
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04152551	PHASE4	RECRUITING	Effects of Bisphosphonates on OI-Related Hearing Loss
NCT00082277	PHASE4	COMPLETED	Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
NCT00130403	PHASE4	COMPLETED	OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women
NCT00221299	PHASE4	COMPLETED	Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use
NCT00372372	PHASE4	COMPLETED	The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment
NCT00377234	PHASE4	COMPLETED	A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
NCT00402441	PHASE4	COMPLETED	Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
NCT00453492	PHASE4	COMPLETED	Risedronate Sodium in Post Menopausal Osteoporosis
NCT00460733	PHASE4	COMPLETED	SOLID-Effect of Risedronate Sodium at Distal Radius in Colle’s Fracture.
NCT00485953	PHASE4	COMPLETED	Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
NCT00544180	PHASE4	TERMINATED	ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week
NCT00549068	PHASE4	COMPLETED	POWER Point of Care Effect on Satisfaction of Treatment
NCT00549965	PHASE4	COMPLETED	Satisfaction and Compliance of Risedronate in PMO
NCT00577395	PHASE4	TERMINATED	Bone Microarchitecture in Osteopenic Postmenopausal Women
NCT00594334	PHASE4	WITHDRAWN	Effect of Actonel on Periodontal Health of Postmenopausal Women
NCT00632216	PHASE4	COMPLETED	A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With Osteoporosis
NCT00772395	PHASE4	COMPLETED	Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty
NCT00790101	PHASE4	TERMINATED	Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00869622	PHASE4	COMPLETED	Antiepileptic Drugs and Osteoporotic Prevention Trial
NCT00887354	PHASE4	COMPLETED	A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture
NCT01215890	PHASE4	COMPLETED	Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn’s Disease
NCT01675297	PHASE4	COMPLETED	Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis
NCT01709110	PHASE4	COMPLETED	VERtebral Fracture Treatment Comparisons in Osteoporotic Women
NCT01904110	PHASE4	COMPLETED	To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women
NCT02148848	PHASE4	UNKNOWN	Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty
NCT03411902	PHASE4	COMPLETED	Weight Loss With Risedronate for Bone Health
NCT04922333	PHASE3	RECRUITING	Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery
NCT00043069	PHASE3	COMPLETED	Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer
NCT00051636	PHASE3	COMPLETED	Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget’s Disease of Bone, Including an Extended Observation Period
NCT00054418	PHASE3	COMPLETED	Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer
NCT00092014	PHASE3	COMPLETED	A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
NCT00103740	PHASE3	COMPLETED	Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget’s Disease of Bone, Including an Extended Observation Period
NCT00106028	PHASE3	COMPLETED	Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
NCT00138866	PHASE3	COMPLETED	Risedronate for the Treatment of Osteoporosis for People With Spinal Cord Injury
NCT00150696	PHASE3	COMPLETED	Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.
NCT00216060	PHASE3	TERMINATED	Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
NCT00247273	PHASE3	COMPLETED	A Study of Monthly Risedronate for Osteoporosis
NCT00268632	PHASE3	COMPLETED	IMPACT Study (Improving Measurements of Persistence on ACtonel Treatment)
NCT00324714	PHASE3	WITHDRAWN	Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS
NCT00343252	PHASE3	COMPLETED	Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis
NCT00345644	PHASE3	COMPLETED	Risedronate in Osteopenic Postmenopausal Women
NCT00353080	PHASE3	COMPLETED	Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
NCT00354302	PHASE3	COMPLETED	Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
NCT00358176	PHASE3	COMPLETED	Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
NCT00365456	PHASE3	COMPLETED	Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)
NCT00386360	PHASE3	COMPLETED	Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method
NCT00426777	PHASE3	COMPLETED	Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
NCT00445575	PHASE2/PHASE3	COMPLETED	Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone
NCT00503399	PHASE3	COMPLETED	Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis
NCT00541658	PHASE3	COMPLETED	A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
NCT00577421	PHASE3	COMPLETED	Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
NCT00619957	PHASE3	COMPLETED	Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis
NCT00859703	PHASE3	COMPLETED	Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
NCT01249261	PHASE3	COMPLETED	Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
NCT01611571	PHASE3	COMPLETED	Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis
NCT01806792	PHASE3	COMPLETED	Post-menopausal Women Osteoporosis(Phase III)
NCT02186600	PHASE3	COMPLETED	Heartland Osteoporosis Prevention Study
NCT02744482	PHASE3	TERMINATED	Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis
NCT07471815	PHASE2	ACTIVE_NOT_RECRUITING	Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
NCT00266708	PHASE1/PHASE2	COMPLETED	Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.
NCT00351091	PHASE2	COMPLETED	Risedronate in Postmenopausal Women With Low Bone Density
NCT00577720	PHASE2	COMPLETED	Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate
NCT00577837	PHASE2	COMPLETED	Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD
NCT00666627	PHASE2	COMPLETED	Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential Effects
NCT03208582	PHASE2	COMPLETED	Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?
NCT03861091	PHASE2	COMPLETED	Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT
NCT00577850	PHASE1	COMPLETED	Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
NCT00699777	PHASE1	COMPLETED	Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects
NCT00717145	PHASE1	COMPLETED	Food Effects on the Relative Bioavailability of Different Dosages of Risedronate
NCT00755872	PHASE1	COMPLETED	Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of Risedronate
NCT00837746	Not specified	COMPLETED	Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate
NCT01077817	Not specified	COMPLETED	Observational Study of Incidence Rates of Esophageal Cancer in Women Taking Medications for the Prevention or Treatment of Osteoporosis (MK-0217A-352)
NCT01406444	Not specified	COMPLETED	IGF-1 and Bone Loss in Women With Anorexia Nervosa
NCT01950169	Not specified	COMPLETED	Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture
NCT04879420	Not specified	COMPLETED	Replication of the VERO Osteoporosis Trial in Healthcare Claims Data
NCT05346419	Not specified	COMPLETED	Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

11 molecules share ≥1 primary target. Top 11 by shared-target count:

Molecule	Source	Status	Shared targets
ALENDRONIC ACID	ChEMBL + PubChem	Phase 4 (approved)	FDPS
IBANDRONIC ACID	ChEMBL + PubChem	Phase 4 (approved)	FDPS
PAMIDRONIC ACID	ChEMBL + PubChem	Phase 4 (approved)	FDPS
ZOLEDRONIC ACID	ChEMBL + PubChem	Phase 4 (approved)	FDPS
ALENDRONATE	ChEMBL	Phase 4 (approved)	FDPS
MINODRONIC ACID	ChEMBL	Phase 4 (approved)	FDPS
NERIDRONIC ACID	ChEMBL	Phase 3	FDPS
PYROPHOSPHORIC ACID	ChEMBL + PubChem	Phase 2 (approved)	FDPS
INCADRONIC ACID	ChEMBL	Phase 2	FDPS
PIRIDRONIC ACID	ChEMBL	Phase 2	FDPS
Lovastatin	PubChem	Approved	FDPS